Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

urial. The model will also promote a new culture open to external collaboration. In line with this approach, a number of alliances were agreed during the period, while existing alliances bore fruit. Excellent Phase II results from the recently-acquired product BSI-201 in triple negative breast cancer were presented to the American Society of Clinical Oncology (ASCO), and the product has since moved into Phase III. A license agreement has been signed with Exelixis, along with an exclusive research collaboration to discover PI3K inhibitors in the treatment of malignant tumors. We have also entered into a collaboration agreement with Kyowa Kirin.
  • Exploring external growth opportunities - In July, our Vaccines business in emerging markets received a significant boost with the acquisition of Shanta Biotechnics in India. This acquisition follows on from those of Zentiva, Kendrick, Medley and BiPar Sciences, Inc. earlier in the year.
  • Adapting our structures to meet the challenges of the future - Implementation of this program is intended to improve the efficiency of our operations, with a target of euro 2 billion of recurring cost savings(6) in 2013 relative to 2008. These savings will be achieved across all Group functions.
  • Our aim is therefore to achieve at least the same level of sales in 2013 vs. 2008 before any significant external growth opportunities. Key growth drivers (Vaccines, Diabetes products, Emerging markets, OTC / OTX, Japan, New launches) aim at largely mitigating the impact on sales of upcoming patent expiries and also providing more sustainable growth with a reduced risk profile as of 2013.

    Our target efficiency savings of 2 billion euros and the contribution of existing key growth drivers aim at offsetting the impact of genericization and achieving a comparable net income level in 2013 vs. 2008. Furthermore, our strong financial position sho
    '/>"/>

    SOURCE sanofi-aventis
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

    Related biology technology :

    1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
    2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
    3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
    4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
    5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
    6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
    7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
    8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
    9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
    10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... -- GlassesOff (OTCBB: GLSO), a visual neuroscience technology ... vision system, announced today a partnership with eight-time All-Star, ... to develop a new mobile app designed for professional ... on-court performance. Vision is the inception of every ... ball or blocking a pass. The critical impact vision speed ...
    (Date:8/27/2015)... Greifensee, Switzerland (PRWEB) , ... August 27, 2015 ... ... input on customers’ weighing needs and expertly narrows down the product choices to ... additional selection criteria pares down the list to models that fit best with ...
    (Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, a commercial ... relationship of genetics and hypertension at the International Academy of Cardiology ... Columbia, Canada. The event, which boasts an extensive overview of the latest research ...
    (Date:8/26/2015)... , Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended June ... in Canadian dollars and presented under International Financial ... activities with respect to our Oral Amp B ... contract manufacturer," said Andrew Rae , President ...
    Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3METTLER TOLEDO Updates Online Scale Selection Tool 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
    ... PRINCETON, N.J., Aug. 30 Medarex, Inc.,(Nasdaq: MEDX ... at the,Thomas Weisel Partners Healthcare Conference at 11:30 AM ... being held at the Four,Seasons Hotel in Boston, Massachusetts. ... for replay through the Webcast page in,the Investor Relations ...
    ... 30 Micromet, Inc.,(Nasdaq: MITI ), a ... antibody-based products for cancer, inflammation and,autoimmune diseases, today ... Officer of Micromet, will present at the Sal. ... Wednesday,September 5, 2007 at 9:50am Eastern time (3:50pm ...
    ... Mass., Aug. 29 Insulet Corporation,(Nasdaq: PODD ... Insulin,Management System, today announced that Duane DeSisto, Chief ... Healthcare,Conference. Mr. DeSisto is scheduled to present an ... on September 6, 2007 at The Four Seasons ...
    Cached Biology Technology:Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007 2Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference 2
    (Date:8/12/2015)... SPRINGS, Florida , August 12, 2015 ... the pace of mobile payment innovation and advanced biometrics ... to replace the way consumers rely on using their ... ahead with reinventing the future for payment services led ... (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
    (Date:8/11/2015)... , August 11, 2015 Today, ZUK announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a prominent smartphone manufacturer in ... selected FPC1 155 for ...
    (Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
    Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
    ... virus in tissues from patients who died of a ... the strain of virus in the measles vaccine caused ... issue of The Journal of Infectious Diseases, now available ... many more cases of the disease, known as subacute ...
    ... emitted about as much carbon monoxide as did human-related ... time period, according to new research by the National ... atmospheric concentrations of ground-level ozone across much of the ... extent to which wildfires contribute to atmospheric pollution, was ...
    ... Abuse Deaths (np-SAD) based at the International Centre for Drug ... has been a decline in the number of drug-related deaths ... drop of eight per cent. The report published today ... by Coroners and Procurators Fiscal in the UK and Islands ...
    Cached Biology News:New study shows measles immunization may prevent fatal brain infection 2NCAR analysis shows widespread pollution from 2004 wildfires 2Continued reduction in the number of drug-related deaths in the UK 2Continued reduction in the number of drug-related deaths in the UK 3
    ... Ek Adaptor encodes a T7 promoter, ... ATG translation initation codon, and an N-terminal ... 109 aa sequence that encodes thioredoxin. Fusion ... enhance solubility of many proteins that are ...
    ...
    The LIC Duet™ Mini Adaptor encodes a T7 promoter, lac operator, ribosome binding site (rbs), and an ATG translation initation codon. This adaptor is designed for expression of a target protei...
    Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
    Biology Products: